Animal imaging in preclinical studies is used to visualize changes at organs, tissue or at a molecular level during drug development. Imaging modalities like micro-PET, MRI and CT allow non-invasive longitudinal studies of animal models.
We are a member of the BMBF network project "Molecular Imaging in Medicine (MoBiMed) - Mechanism of targeting Angiogenesis for Diagnostics and Therapy" funded by the german government. Our part in this research project consortium is concerned with imaging applications of tumor angiogenesis. Using multi-modal acquisition techniques, tumor growth and marker specificity is evaluated and analysed.
For this project, we have developed an imaging platform for pre-clinical animal studies. It allows the visualization and processing of DICOM or proprietary animal image formats of different in-vivo scanners. It also supports tumor segmentation and fusion techniques for different modalities.
![]()
The left plot shows a comparison between a manual- and an automated tumor segmentation used for a SUV analysis. The tumor ROI is used to compute mean standardized uptake values in a 4-D PET image. Each single curve represents an average of three different animal studies. The specificity of the radiopharmaceutical is evaluated by comparing a control to a blocking angiogenesis study. The manual anti-angiogenesis study takes several hours, while the automated evaluation takes only minutes providing comparable results.